Want to see IN:JUBLINGREA full AI Analyst Report?
Top Page
Jubilant Ingrevia Ltd.
(JUBLINGREA)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹700.00
▼(-3.58% Downside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by weak cash-flow quality and volatility despite positive operating cash flow, alongside soft technical momentum (below key moving averages with negative MACD). A manageable balance sheet and modest revenue growth provide partial support, but a high P/E and low dividend yield further limit the score.
Positive Factors
Revenue Stabilization
Revenue has returned to growth after two weaker periods, indicating stabilization in demand across the company’s specialty chemicals and ingredient businesses. Although the increase is modest, renewed top-line expansion can support capacity utilization and provide a base for future product-mix improvement.
Negative Factors
Weak Cash Conversion
Operating cash flow remains consistently positive, but its level relative to reported net income is weak. Persistently low cash conversion can limit internally funded growth, reduce flexibility in capital allocation, and make accounting earnings a less reliable measure of durable financial strength.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Stabilization
Revenue has returned to growth after two weaker periods, indicating stabilization in demand across the company’s specialty chemicals and ingredient businesses. Although the increase is modest, renewed top-line expansion can support capacity utilization and provide a base for future product-mix improvement.
Read all positive factors
Jubilant Ingrevia Ltd. (JUBLINGREA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹101.93B
Dividend Yield0.76%
Average Volume (3M)22.93K
Price to Earnings (P/E)33.4
Beta (1Y)1.17
Revenue Growth10.96%
EPS Growth11.16%
CountryIN
Employees2,185
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)19.54
Shares Outstanding159,281,140
10 Day Avg. Volume44,444
30 Day Avg. Volume22,930
Financial Highlights & Ratios
PEG Ratio2.89
Price to Book (P/B)2.75
Price to Sales (P/S)1.96
P/FCF Ratio52.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)28.26
Revenue Forecast (FY)₹52.68B
Jubilant Ingrevia Ltd. Business Overview & Revenue Model
Company Description
Jubilant Ingrevia Limited, established in 2019 and based in Noida, India, is a global supplier of life science products and comprehensive solutions. The company's operations are divided into three core divisions: Specialty Chemicals, Nutrition & H...
How the Company Makes Money
Jubilant Ingrevia makes money primarily by manufacturing and selling specialty chemicals and ingredient products to business customers (B2B) in India and international markets. Its revenue model is largely product-sales driven: (1) Sales of specia...
Jubilant Ingrevia Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
72
Positive
Cash Flow
49
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.28B | 43.88B | 41.24B | 41.00B | 47.40B | 49.14B |
| Gross Profit | 17.06B | 10.74B | 19.00B | 18.50B | 20.44B | 19.56B |
| EBITDA | 6.50B | 5.94B | 5.56B | 4.56B | 5.79B | 8.59B |
| Net Income | 3.09B | 2.78B | 2.51B | 1.83B | 3.07B | 4.77B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 54.84B | 50.32B | 47.32B | 42.59B | 37.97B |
| Cash, Cash Equivalents and Short-Term Investments | 1.90B | 1.90B | 1.15B | 828.36M | 1.08B | 454.69M |
| Total Debt | 0.00 | 7.92B | 7.64B | 7.40B | 4.07B | 2.38B |
| Total Liabilities | -31.26B | 23.58B | 21.05B | 19.94B | 15.93B | 13.64B |
| Stockholders Equity | 31.26B | 31.26B | 29.27B | 27.37B | 26.66B | 24.33B |
Cash Flow | ||||||
| Free Cash Flow | -365.90M | 1.63B | 1.42B | -1.38B | -189.30M | 2.23B |
| Operating Cash Flow | 970.80M | 4.62B | 5.08B | 4.30B | 4.62B | 4.53B |
| Investing Cash Flow | -962.50M | -2.77B | -3.93B | -5.70B | -4.72B | -718.56M |
| Financing Cash Flow | -495.40M | -923.50M | -1.29B | 1.44B | 416.00M | -4.18B |
Jubilant Ingrevia Ltd. Technical Analysis
Negative
726.00
Price Trends
698.53
Negative
687.53
Negative
666.94
Negative
Market Momentum
-15.92
Negative
40.90
Neutral
69.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLINGREA, the sentiment is Negative. The current price of 726 is above the 20-day moving average (MA) of 654.75, above the 50-day MA of 698.53, and above the 200-day MA of 666.94, indicating a bearish trend. The MACD of -15.92 indicates Negative momentum. The RSI at 40.90 is Neutral, neither overbought nor oversold. The STOCH value of 69.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JUBLINGREA.
Jubilant Ingrevia Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹147.50B | 52.35 | ― | 0.55% | -6.72% | -22.67% | |
67 Neutral | ₹279.32B | -87.14 | ― | 0.07% | 0.78% | -420.81% | |
56 Neutral | ₹25.27B | 36.20 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹148.63B | 66.42 | ― | 0.34% | -3.41% | -56.45% | |
53 Neutral | ₹101.93B | 33.43 | ― | 0.76% | 10.96% | 11.16% | |
48 Neutral | ₹181.69B | -358.87 | ― | ― | 27.15% | 40.46% |
* General Sector Average
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
653.75
9.66
1.50%
IN:CONCORDBIO
Concord Biotech Ltd.
1,373.40
-249.38
-15.37%
IN:DCAL
Dishman Carbogen Amcis Ltd.
156.95
-119.45
-43.22%
IN:PPLPHARMA
Piramal Pharma Limited
206.30
7.00
3.51%
IN:SYNGENE
Syngene International Ltd.
364.80
-264.77
-42.06%
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,525.45
-260.40
-14.58%
Jubilant Ingrevia Ltd. Corporate Events
Jubilant Ingrevia to Buy 40% Stake in Zettaone, Pushing into Electronics and Semiconductor Services
Aug 18, 2026
Jubilant Ingrevia Limited has approved a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Pvt. Ltd., an integrated electronics design and manufacturing platform, for approximately ₹189.2 crore in cash...
Jubilant Ingrevia Publishes AGM, E-Voting and Dividend Notice
Aug 2, 2026
Jubilant Ingrevia has notified stock exchanges that it has published newspaper advertisements announcing its seventh annual general meeting, along with related information on e-voting, record date and final dividend details for the 2025-26 financi...
Jubilant Ingrevia Files Earnings Call Transcript for June Quarter
Jul 27, 2026
Jubilant Ingrevia Limited operates in the chemicals and ingredients sector, providing specialty chemicals and related solutions to industrial customers. Listed on BSE and NSE in India, the company engages actively with institutional investors and ...
Jubilant Ingrevia Grants New Employee Stock Options Under 2021 Scheme
Jul 22, 2026
Jubilant Ingrevia Ltd. operates in the specialty chemicals and life sciences ingredients sector, supplying a range of chemical-based inputs to industrial and pharmaceutical customers. The company focuses on value-added chemical products and interm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.